JAC Advance Access originally published online on May 4, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):983-988; doi:10.1093/jac/dki129
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis
1 Department of Microbiology, 220 Nash Hall, Oregon State University, Corvallis, OR 97331-3804, USA; 2 AVI BioPharma, Corvallis, OR, USA
* Corresponding author. Email: gellerb{at}orst.edu
Objectives: Antisense phosphorodiamidate morpholino oligomers (PMOs) are synthetic DNA mimics that specifically inhibit gene expression in pure cultures of Escherichia coli. Previously, an 11 base PMO targeted to an essential gene (acpP) for phospholipid biosynthesis was shown to inhibit growth of a pure culture of E. coli AS19, which has an abnormally permeable outer membrane. The objectives of experiments in this report are to show that the AcpP PMO significantly inhibits growth of strain SM105, which has a normal, intact outer membrane, both in pure culture and in infected mice.
Methods: In pure culture, SM105 was grown in rich broth supplemented with 20 µM AcpP PMO, and growth was monitored by optical density and viable cell count. Mice were infected by intraperitoneal injection with a non-lethal inoculum of either E. coli AS19 or SM105. Following infection, mice were treated intraperitoneally with 300 µg of the 11 base antisense PMO targeted to acpP, a scrambled sequence PMO or PBS.
Results: Growth of SM105 was slower and viable cells were significantly reduced by up to 61% in pure cultures supplemented with AcpP PMO compared with untreated cultures or cultures supplemented with a scrambled sequence PMO. A single dose of AcpP PMO reduced peritoneal cfu of E. coli AS19 about 39- to 600-fold compared with controls at 2, 7, 13 and 23 h after treatment. The same PMO significantly reduced cfu of E. coli SM105 75% compared with controls at 12 h after treatment. However, there was no difference in cfu at 2, 7 or 24 h. A second dose at 24 h again reduced SM105 cfu about 10-fold by 48 h post-infection. In other experiments with infected mice, multiple doses of AcpP PMO sustained the 
10-fold reduction in SM105 cfu at 6, 12 and 24 h post-infection. Compared with equivalent (micromolar) doses of ampicillin, AcpP PMO was significantly more effective at all time points. Specificity of PMO inhibition was shown in other experiments by treating infected mice with a PMO targeted to a non-essential reporter gene for luciferase. A luciferase-specific PMO reduced both the amount and activity of luciferase to the same extent, whereas scrambled PMO had no effect.
Conclusions: An 11 base antisense PMO targeted to acpP significantly inhibited viability of a strain of E. coli with a normal, intact outer membrane both in pure culture and in infected mice. Inhibition by PMOs was sequence-specific.
Keywords: PMO , antibiotics , gene-specific , bacterial growth inhibition
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. L. Mellbye, D. D. Weller, J. N. Hassinger, M. D. Reeves, C. E. Lovejoy, P. L. Iversen, and B. L. Geller Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo J. Antimicrob. Chemother., November 1, 2009; (2009) dkp392v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Mitev, B. L. Mellbye, P. L. Iversen, and B. L. Geller Inhibition of Intracellular Growth of Salmonella enterica Serovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3700 - 3704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Meng, H. Wang, Z. Hou, T. Chen, J. Fu, X. Ma, G. He, X. Xue, M. Jia, and X. Luo Novel Anion Liposome-Encapsulated Antisense Oligonucleotide Restores Susceptibility of Methicillin-Resistant Staphylococcus aureus and Rescues Mice from Lethal Sepsis by Targeting mecA Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2871 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Mellbye, S. E. Puckett, L. D. Tilley, P. L. Iversen, and B. L. Geller Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo Antimicrob. Agents Chemother., February 1, 2009; 53(2): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Tilley, B. L. Mellbye, S. E. Puckett, Patrick. L. Iversen, and B. L. Geller Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli J. Antimicrob. Chemother., January 1, 2007; 59(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. R. Faridani, A. Nikravesh, D. P. Pandey, K. Gerdes, and L. Good Competitive inhibition of natural antisense Sok-RNA interactions activates Hok-mediated cell killing in Escherichia coli Nucleic Acids Res., November 6, 2006; 34(20): 5915 - 5922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Tilley, O. S. Hine, J. A. Kellogg, J. N. Hassinger, D. D. Weller, P. L. Iversen, and B. L. Geller Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2789 - 2796. [Abstract] [Full Text] [PDF]
|
|